It is one of the first development pre-clinical tests one does when moving a drug to human testing - ADME. I find it quite preposterous that you'd assume your new optimised lead will follow the same path as earlier compounds. You'd be hard pressed to find any company in the pharmaceutical sphere that would make those sorts of assumptions.
Add to My Watchlist
What is My Watchlist?